Literature DB >> 21623852

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.

G Vernon1, A Baranova, Z M Younossi.   

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease, and its worldwide prevalence continues to increase with the growing obesity epidemic. This study assesses the epidemiology of NAFLD in adults based on clinical literature published over the past 30 years. AIM: To review epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults based on clinical literature published over the past 30 years.
METHODS: An in-depth search of PubMed (1980-2010) was based on five search terms: 'non-alcoholic fatty liver disease' OR 'non-alcoholic steatohepatitis' OR 'fatty liver' OR 'steatosis' AND 'incidence' [MeSH Terms] OR 'prevalence' [MeSH Terms] OR 'natural history'. Studies of paediatric cohorts were excluded. Articles were categorised by topic and summarised, noting generalisations concerning their content.
RESULTS: Four study categories included NAFLD incidence, prevalence, risk factors and natural history. Studies related to NAFLD prevalence and incidence indicate that the diagnosis is heterogeneous and relies on a variety of assessment tools, including liver biopsy, radiological tests such as ultrasonography, and blood testing such as liver enzymes. The prevalence of NAFLD is highest in populations with pre-existing metabolic conditions such as obesity and type II diabetes. Many studies investigating the natural history of NAFLD verify the progression from NASH to advanced fibrosis and hepatocellular carcinoma.
CONCLUSIONS: Non-alcoholic fatty liver disease is the most common cause of elevated liver enzymes. Within the NAFLD spectrum, only NASH progresses to cirrhosis and hepatocellular carcinoma. With the growing epidemic of obesity, the prevalence and impact of NAFLD continues to increase, making NASH potentially the most common cause of advanced liver disease in coming decades.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21623852     DOI: 10.1111/j.1365-2036.2011.04724.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  1018 in total

1.  Canadian regulations and legal ramifications for hepatic encephalopathy: a descriptive analysis.

Authors:  Henry H Nguyen; Mark G Swain; Philip Wong; Stephen E Congly
Journal:  CMAJ Open       Date:  2018-12-03

2.  Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions.

Authors:  Daniel L Motola; Peter Caravan; Raymond T Chung; Bryan C Fuchs
Journal:  Curr Pathobiol Rep       Date:  2014-12-01

Review 3.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

4.  How bariatric surgery affects liver volume and fat density in NAFLD patients.

Authors:  Ran B Luo; Toshiaki Suzuki; Jonathan C Hooker; Yesenia Covarrubias; Alexandra Schlein; Shanglei Liu; Jeffrey B Schwimmer; Scott B Reeder; Luke M Funk; Jacob A Greenberg; Guilherme M Campos; Bryan J Sandler; Santiago Horgan; Claude B Sirlin; Garth R Jacobsen
Journal:  Surg Endosc       Date:  2017-12-07       Impact factor: 4.584

Review 5.  Relationships between diabetes and cognitive impairment.

Authors:  Suzanne M de la Monte
Journal:  Endocrinol Metab Clin North Am       Date:  2013-12-12       Impact factor: 4.741

Review 6.  Clinical approaches to non-alcoholic fatty liver disease.

Authors:  Katherine J P Schwenger; Johane P Allard
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 7.  Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Xue-Qun Zhang; Cheng-Fu Xu; Chao-Hui Yu; Wei-Xing Chen; You-Ming Li
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

8.  Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease.

Authors:  N S Patel; M R Peterson; D A Brenner; E Heba; C Sirlin; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2013-02-05       Impact factor: 8.171

9.  The effect of miRNA-122 in regulating fat deposition in a cell line model.

Authors:  Yu-Qiang Nie; Jie Cao; Yong-Jian Zhou; Xia Liang; Yan-Lei Du; Yu-Jui Yvonne Wan; Yu-Yuan Li
Journal:  J Cell Biochem       Date:  2014-05       Impact factor: 4.429

10.  Probiotics Supplemented with Omega-3 Fatty Acids are More Effective for Hepatic Steatosis Reduction in an Animal Model of Obesity.

Authors:  Nazarii Kobyliak; Tetyana Falalyeyeva; Petro Bodnar; Tetyana Beregova
Journal:  Probiotics Antimicrob Proteins       Date:  2017-06       Impact factor: 4.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.